foxo4-dri cancer The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI 10mg
FOXO4 DRI 10mg FOXO4 DRI Peptide 10 mg Development of a novel senolytic by precise disruption of FOXO4 p53 complex eBioMedicine Peptide inhibitors targeting FOXO4 p53 interactions and inducing senescent cancer cell specific apoptosis bioRxiv
Pay in 4 interest-free payments of $6.23 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8



